Human Nuclear Autoantibody (IgG) ELISA kit (CAT#: NAK-008)

This product is a qualitative ELISA kit for the determination of Nuclear Autoantibody in human Plasma or Serum.

Specifications
Sensitivity	Qualitative
Assay Type	ELISA
Pack size	1×96 wells
Species Reactivity	Human
Antibody Type	IgG
Contents	HRP-conjugate Positive Control Negative Control Adhesive Strip (For 96 wells) Coated assay plate Wash Buffer (25 x concentrate) Stop Solution Sample Diluent Substrate A Substrate B
Sample Requirement	Serum
Storage	Short term: 4°C, Long term: See manual.

Target Information
Target	Nuclear autoantibody
Introduction	The purpose of an antinuclear antibody test is to detect, measure, and evaluate antinuclear antibodies in a patient's blood sample. ANA testing can assist health care providers in diagnosing autoimmune disorders and provide information that may be helpful in determining a patient's specific type of autoimmune disorder.

Q&A
Customer Reviews
Downloadable Resources
Published Data

Q: What is the main application of the Human Nuclear Autoantibody (IgG) ELISA kit?
A: The main application of the Human Nuclear Autoantibody (IgG) ELISA kit is the qualitative detection of nuclear autoantibodies in human plasma or serum. This is pivotal in the clinical diagnosis and management of autoimmune disorders. By identifying the presence of antinuclear antibodies (ANAs), health care providers can better understand the autoimmune activities in patients, aiding in the diagnosis of conditions like systemic lupus erythematosus (SLE), rheumatoid arthritis, and other autoimmune diseases. This kit's ability to provide qualitative results is crucial for the early detection and intervention in these conditions.

Q: How does the Human Nuclear Autoantibody ELISA kit work?
A: The Human Nuclear Autoantibody ELISA kit works by using a coated assay plate where samples of human serum or plasma are added. These samples react with the antigens coated on the plate if nuclear autoantibodies are present. The reaction is then detected using an HRP-conjugate, which binds to the autoantibodies. Substrates A and B are added, leading to a color change that indicates the presence of nuclear autoantibodies. Positive and negative controls are used to ensure the assay's accuracy, with the results being qualitative.

Q: What are the contents included in the Human Nuclear Autoantibody (IgG) ELISA kit?
A: The Human Nuclear Autoantibody (IgG) ELISA kit contains components such as HRP-conjugate, Positive and Negative Control, Adhesive Strip for 96 wells, Coated assay plate, Wash Buffer (25 x concentrate), Stop Solution, Sample Diluent, Substrate A, and Substrate B.

Q: Why is it important to detect nuclear autoantibodies?
A: Detecting nuclear autoantibodies is crucial because their presence is often associated with a variety of autoimmune disorders. These antibodies target the body's own nuclear materials, leading to inflammation and damage to various organs and tissues. Identifying these autoantibodies helps healthcare providers diagnose conditions such as systemic lupus erythematosus, Sjogren's syndrome, scleroderma, and rheumatoid arthritis. Early detection through testing can lead to timely intervention, potentially improving patient outcomes by managing symptoms and preventing severe disease progression.

Excellent sensitivity and reactivity
The Human Nuclear Autoantibody ELISA kit provided excellent sensitivity and reactivity for the detection of Nuclear Autoantibody in human plasma or serum. All the necessary components are provided in the kit, which is very convenient and makes the procedure straightforward. The assay was qualitative and gave reliable results each time. The storage conditions are also simple, allowing for short term storage at 4°C, and for the long term, you just need to refer to the manual. Highly recommended!

02/20/2023

Streamlined workflow for autoimmune research
In our laboratory, the Human Nuclear Autoantibody (IgG) ELISA kit has significantly streamlined our research on autoimmune disorders. The kit's user-friendly components and clear instructions have reduced our assay setup time, allowing us to process samples more efficiently. The coated assay plate, combined with the high-quality HRP-conjugate, wash buffer, and substrates, ensures precise and accurate measurements every time. Our research has benefitted greatly from the kit's qualitative sensitivity, enabling us to confidently analyze the prevalence and significance of nuclear autoantibodies in our studies.

04/22/2023

Confident and consistent results
The kit provides all the necessary components, ensuring the accuracy of assays. With it being highly species-specific to humans, the product has always provided confident results for all my tests. And with proper storage, the kit consistently delivers high-quality outcomes. It's an essential tool in evaluating antinuclear antibodies, providing vital information for our autoimmune disorder studies.

01/25/2024

Click the button below to contact us or submit your feedback about this product.

Datasheet NAA Detection Kits Flyer

Title: Distribution of IgG Subclass Anti-nuclear Antibodies (ANAs) in Systemic Lupus Erythematosus

Journal: Lupus

Authors: Yanli Zeng, Yan Zhang, Qinggui Chen, et al.

Objective: Our study purpose was to detect the distribution of anti-nuclear antibody (ANA) IgG subclasses in patients with systemic lupus erythematosus (SLE) and to evaluate their influence on the inflammatory process in SLE.

Methods: We determined the serum levels of ANA IgG subclasses from 70 SLE patients, 25 patients with other autoimmune diseases (OAD), and 25 healthy controls using ELISA. The serum level of total ANA IgG and the avidity of ANA IgG, dsDNA IgG, and dsDNA IgG subclasses were analysed by ELISA.

Results: The results indicated that levels of four ANA IgG subclasses (IgG1, IgG2, IgG3 and IgG4) and total IgG were significantly higher in SLE patients than in OAD patients and healthy controls (p < 0.001). Moreover, the level of each ANA IgG subclass and the prevalence of high-avidity IgG ANAs (HA IgG ANAs) were significantly higher in the active cases than in the inactive cases of SLE and LN. Furthermore, level of ANA IgG subclasses decreased as level of dsDNA IgG subclasses decreased in 30 patients with SLE. In comparison, ANA IgG3 was significantly effective in high-dose prednisone combined with hydroxychloroquine (p = 0.025). Additionally, it revealed that level of dsDNA IgG had a significant influence on four ANA IgG subclasses, especially on ANA IgG3 (β coefficient = 0.649, p < 0.001). Level of ANA IgG3 was also positively related to the serum level of dsDNA IgG (r = 0.729, p < 0.001) and RAI of HA IgG ANAs (r = 0.504, p < 0.001). However, the level of ANA IgG4 was positively related to the serum level of albumin (r = 0.572, p < 0.001) and RAI of HA IgG ANAs (r = 0.549, p < 0.001). Moreover, the results revealed that cutaneous and renal involvement were mainly associated with the ANA IgG1 and IgG4 subclasses. Although, arthritic involvement was mainly associated with ANA IgG3.

Conclusions: First, we demonstrated that the ANA IgG subclasses were diagnostic tools in SLE patients. Furthermore, HA IgG ANAs might affect the distribution of ANA IgG3 and IgG4. Moreover, ANA IgG3 might play a particular role in the activity of SLE disease and therapy. Therefore, an altered ANA IgG subclass distribution might be a risk factor influencing the inflammatory process in SLE.

Distribution of ANA IgG subclass in patients with SLE and in different clinical manifestations with SLE.

For Research Use Only | Not For Clinical Use

Services:

Resource:

Pathways

Applications:

Online Inquiry